Development of RNA Base Editing Technologies for Precision Medicines with Axiomer® and Trident® presented at TIDES USA 2022 by Gerard Platenburg - ProQR Therapeutics.
… Axiomer Investor Call ProQR management will host an investor conference call and … date. Download the presentation About Axiomer ® ProQR is pioneering a next-generation RNA editing technology … jeu 09/09/2021 - 14:15 - jeu 09/09/2021 - 15:15 ProQR management will host an investor conference call and …
ProQR will review the recently reported AX-0810 Phase 1 target engagement data and discuss the translational rationale and clinical development strategy for NTCP modulation in biliary atresia, including the framework for evaluating upcoming next-generation AX-0811 Phase 1 data and its potential to treat cholestatic disease.